175 results on '"Kumada, Hiromitsu"'
Search Results
2. A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116.
- Author
-
Kudo, Masatoshi, Finn, Richard S., Ikeda, Masafumi, Sung, Max W., Baron, Ari D., Okusaka, Takuji, Kobayashi, Masahiro, Kumada, Hiromitsu, Kaneko, Shuichi, Pracht, Marc, Meyer, Tim, Nagao, Satoshi, Saito, Kenichi, Mody, Kalgi, Ramji, Zahra, Dubrovsky, Leonid, and Llovet, Josep M.
- Subjects
PROGRESSION-free survival ,OVERALL survival ,HEPATOCELLULAR carcinoma ,PATIENT safety ,ANTINEOPLASTIC agents - Abstract
Introduction: Lenvatinib (dosing for patients who weigh ≥60 kg was 12 mg/day; for patients who weigh <60 kg, the dose was 8 mg/day) plus pembrolizumab 200 mg once every 3 weeks demonstrated antitumor activity and a manageable safety profile in patients with first-line unresectable hepatocellular carcinoma (uHCC) in the open-label phase 1b Study 116/KEYNOTE-524 (primary analysis data cutoff date: October 31, 2019; median follow-up: 10.6 months). This analysis (updated data cutoff date: March 31, 2021) reports efficacy results from 17 months of additional follow-up time. Methods: 100 patients with uHCC were included in the primary analysis (median follow-up: 27.6 months). Endpoints included overall survival (OS), investigator-assessed progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR) per modified RECIST. Landmark analyses of OS by the best response at 3 and 9 months were performed. Pembrolizumab antidrug antibodies (ADAs) and concentrations were also measured (cutoff date: August 7, 2020). Results: ORR was 43.0% (95% CI 33.1–53.3%) and median DOR was 17.1 months (95% CI 6.9–19.3 months). Median PFS and OS were 9.3 months (95% CI 7.4–9.8 months) and 20.4 months (95% CI 14.4–25.9 months), respectively. No treatment-emergent ADAs were detected. Conclusion: Results show a sustained treatment effect with lenvatinib plus pembrolizumab in patients with uHCC in the first-line setting. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT
- Author
-
Okusaka, Takuji, Ikeda, Kenji, Kudo, Masatoshi, Finn, Richard, Qin, Shukui, Han, Kwang-Hyub, Cheng, Ann-Lii, Piscaglia, Fabio, Kobayashi, Masahiro, Sung, Max, Chen, Minshan, Wyrwicz, Lucjan, Yoon, Jung-Hwan, Ren, Zhenggang, Mody, Kalgi, Dutcus, Corina, Tamai, Toshiyuki, Ren, Min, Hayato, Seiichi, and Kumada, Hiromitsu
- Published
- 2021
- Full Text
- View/download PDF
4. A new imaging classification for safer radial access visceral intervention of the liver and optimal case selection: A preliminary report.
- Author
-
Kawamura, Yusuke, Akuta, Norio, Fujiyama, Shunichiro, Hosaka, Tetsuya, Saitoh, Satoshi, Sezaki, Hitomi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Ikeda, Kenji, Arase, Yasuji, and Kumada, Hiromitsu
- Subjects
IMAGE recognition (Computer vision) ,CELIAC artery ,RADIAL artery ,SUBCLAVIAN artery ,MESENTERIC artery ,TELERADIOLOGY ,INTERVENTIONAL radiology - Abstract
Aim: The aim of this study was to evaluate the use of a new classification for safer transradial access hepatic interventional radiology, based on preoperative evaluation of the location of the left subclavian artery bifurcation in the aortic arch. Methods: A total of 38 consecutive patients with hepatocellular carcinoma and 74 sessions of radial access for visceral intervention (R.A.V.I.) were reviewed. We classified the location of the left subclavian artery bifurcation in the aortic arch in three areas using an oblique view computed tomography image matched with the curve of the aortic arches according to a new criteria Three Areas Criteria For R.A.V.I. (named "TAC‐F‐R"), and measured the required time from initial left radial artery arteriography to celiac artery or superior mesenteric artery arteriography. Results: The median time required for left radial artery arteriography to the celiac artery or superior mesenteric artery arteriography in each of the three areas were: area A, 0:11:10 (h, min, s); area B, 0:14:44; and area C, 0:31:51. There were significant differences between each area after Bonferroni correction (p < 0.01; A vs. B, p = 0.086; A vs. C, p = 0.001; and B vs. C, p = 0.045), with areas A and B requiring a significantly shorter time. Finally, no patients showed neurogenic disfunction within 1 week after the R.A.V.I. procedure. Conclusions: The new classification, "TAC‐F‐R," for safer transradial access hepatic interventional radiology is effective for avoiding difficult cases, and selects more suitable patients with hepatocellular carcinoma for the R.A.V.I. procedure. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication
- Author
-
Miki, Daiki, Akita, Tomoyuki, Kurisu, Akemi, Kawaoka, Tomokazu, Nakajima, Tomoaki, Hige, Shuhei, Karino, Yoshiyasu, Toyoda, Hidenori, Kumada, Takashi, Tsuge, Masataka, Hiramatsu, Akira, Imamura, Michio, Aikata, Hiroshi, Hayes, Clair Nelson, Honda, Koichi, Seike, Masataka, Akuta, Norio, Kobayashi, Mariko, Kumada, Hiromitsu, Tanaka, Junko, and Chayama, Kazuaki
- Published
- 2020
- Full Text
- View/download PDF
6. Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study
- Author
-
Fujiyama, Shunichiro, Akuta, Norio, Sezaki, Hitomi, Kobayashi, Mariko, Kawamura, Yusuke, Hosaka, Tetsuya, Kobayashi, Masahiro, Saitoh, Satoshi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu
- Published
- 2021
- Full Text
- View/download PDF
7. REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
- Author
-
Yamashita, Tatsuya, Kudo, Masatoshi, Ikeda, Kenji, Izumi, Namiki, Tateishi, Ryosuke, Ikeda, Masafumi, Aikata, Hiroshi, Kawaguchi, Yasunori, Wada, Yoshiyuki, Numata, Kazushi, Inaba, Yoshitaka, Kuromatsu, Ryoko, Kobayashi, Masahiro, Okusaka, Takuji, Tamai, Toshiyuki, Kitamura, Chifumi, Saito, Kenichi, Haruna, Katsuya, Okita, Kiwamu, and Kumada, Hiromitsu
- Published
- 2020
- Full Text
- View/download PDF
8. Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma.
- Author
-
Kawamura, Yusuke, Akuta, Norio, Shindoh, Junichi, Matsumura, Masaru, Okubo, Satoshi, Tominaga, Licht, Fujiyama, Shunichiro, Hosaka, Tetsuya, Saitoh, Satoshi, Sezaki, Hitomi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Ikeda, Kenji, Arase, Yasuji, Hashimoto, Masaji, Kozuka, Takuyo, and Kumada, Hiromitsu
- Subjects
THERAPEUTIC use of monoclonal antibodies ,DRUG efficacy ,KRUSKAL-Wallis Test ,CANCER chemotherapy ,MULTIVARIATE analysis ,LOG-rank test ,ANTINEOPLASTIC agents ,FISHER exact test ,TUMOR classification ,CANCER patients ,PROTEIN-tyrosine kinase inhibitors ,TREATMENT failure ,RESEARCH funding ,SURVIVAL analysis (Biometry) ,DESCRIPTIVE statistics ,LACTATE dehydrogenase ,KAPLAN-Meier estimator ,BEVACIZUMAB ,DATA analysis software ,FRIEDMAN test (Statistics) ,DRUG side effects ,HEPATOCELLULAR carcinoma ,OVERALL survival ,PROPORTIONAL hazards models - Abstract
Simple Summary: The Barcelona clinic liver cancer (BCLC) system is used widely for staging hepatocellular carcinomas (HCCs). However, it is questionable that for patients classified as BCLC stage C, control of intrahepatic targets using various treatment procedures is not the main topic of discussion, whereas the importance of intrahepatic tumor control in patients with extrahepatic tumor spread is reviewed. Therefore, this study analyzed the data of 64 consecutive BCLC stage C patients with intrahepatic target nodules who received systemic therapy and evaluated the efficacy of the combined use of systemic sequential therapy, including more than two agents, and locoregional treatment administered after initiation of systemic therapy. We showed that the combined use of systemic sequential therapy of more than two agents and locoregional-treatment improved overall survival in BCLC stage C HCC patients with intrahepatic target nodules who had previously received systemic therapy-based treatment. Background: The aim of this study was to evaluate the clinical impact of a combination of systemic sequential therapy and locoregional therapy on the long-term survival of patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC). Methods: Sixty-four consecutive patients with intrahepatic target nodules who had initially received systemic therapy (lenvatinib and atezolizumab plus bevacizumab) were reviewed. The clinical impact of the combined use of systemic sequential therapy and locoregional therapy was evaluated by determining overall survival (OS). The combined use of systemic sequential therapy with more than two agents and locoregional treatment was defined as multidisciplinary combination therapy (MCT), while only systemic sequential therapy and repeated locoregional-treatment was defined as a single treatment procedure (STP). Results: R0 resection, MCT, and STP resulted in significantly better OS compared with no additional treatment (median OS, not reached vs. 18.2 months and 12.6 vs. 8.1 months, respectively; p = 0.002). Multivariate analysis confirmed that the use of R0 resection and MCT were associated with better OS (hazard ratio [HR]; 0.053, p = 0.006 and 0.189, p < 0.001, respectively) compared with that for STP (HR; 0.279, p = 0.003). Conclusions: MCT is may effective in patients with BCLC stage C HCC and intrahepatic target nodules who have previously received systemic therapy-based treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
- Author
-
Ikeda, Kenji, Kudo, Masatoshi, Kawazoe, Seiji, Osaki, Yukio, Ikeda, Masafumi, Okusaka, Takuji, Tamai, Toshiyuki, Suzuki, Takuya, Hisai, Takashi, Hayato, Seiichi, Okita, Kiwamu, and Kumada, Hiromitsu
- Published
- 2017
- Full Text
- View/download PDF
10. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan
- Author
-
Akuta, Norio, Kawamura, Yusuke, Suzuki, Fumitaka, Saitoh, Satoshi, Arase, Yasuji, Kunimoto, Hideo, Sorin, Yushi, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Kobayashi, Mariko, Ikeda, Kenji, and Kumada, Hiromitsu
- Published
- 2016
- Full Text
- View/download PDF
11. The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based Analysis.
- Author
-
Muraishi, Nozomu, Kawamura, Yusuke, Akuta, Norio, Shindoh, Junichi, Matsumura, Masaru, Okubo, Satoshi, Fujiyama, Shunichiro, Hosaka, Tetsuya, Saitoh, Satoshi, Sezaki, Hitomi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Ikeda, Kenji, Arase, Yasuji, Hashimoto, Masaji, Yasuda, Ichiro, and Kumada, Hiromitsu
- Subjects
VASCULAR endothelial growth factor antagonists ,ANGIOGRAPHY ,DRUG efficacy ,NEOVASCULARIZATION inhibitors ,BLOOD vessels ,RETROSPECTIVE studies ,PROTEIN-tyrosine kinase inhibitors ,CANCER patients ,PRE-tests & post-tests ,COMPARATIVE studies ,BLOOD circulation ,RESEARCH funding ,EMERGENCY medical services ,DESCRIPTIVE statistics ,COMPUTED tomography ,PROGRESSION-free survival ,HEPATOCELLULAR carcinoma ,PHARMACODYNAMICS ,EVALUATION - Abstract
Introduction: When lenvatinib is administered to people with hepatocellular carcinoma (HCC), tumor blood flow is reduced due to the inhibition of the vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR). Few studies have examined the decrease in tumor blood flow with respect to changes in tumor blood vessels (TBVs) in clinical practice. We investigated the mechanism of tumor blood flow control by investigating changes in the diameter of relatively large TBVs in large-sized lesions with high blood flow. Methods: From January 2011 to October 2021, patients receiving lenvatinib for unresectable intrahepatic HCC at Toranomon Hospital, Tokyo, Japan, were considered for inclusion. We investigated the TBV diameter in the arterial phase of dynamic computed tomography before treatment and its change over time (2–12 weeks after lenvatinib initiation). The relationship between changes in TBV diameter and prognosis was also examined. Results: Of 114 patients treated with lenvatinib for HCC, 26 patients who had intrahepatic lesions with a tumor diameter of 30 mm or more enrolled in the study. The median tumor and TBV diameters before treatment were 58 mm and 2.55 mm, respectively. Twenty-five patients (96%) had a shrinkage in TBV diameter 2–12 weeks after lenvatinib administration. The maximum TBV diameter shrinkage of 20% or more was observed in 19 patients (73%), and progression-free survival was prolonged in these patients compared to the group with less than 20% TBV diameter shrinkage (p = 0.039). Discussion/Conclusion: Due to the antiangiogenic effect of lenvatinib, a shrinkage in the TBV diameter of HCC was observed. The shrinkage of TBV may be regarded as a process of normalization of TBVs. The shrinkage of TBVs in imaging analysis may be associated with improved prognosis; however, additional studies are still required. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial
- Author
-
Okita, Kiwamu, Izumi, Namiki, Ikeda, Kenji, Osaki, Yukio, Numata, Kazushi, Ikeda, Masafumi, Kokudo, Norihiro, Imanaka, Kazuho, Nishiguchi, Shuhei, Kondo, Shunsuke, Nishigaki, Yoichi, Shiomi, Susumu, Ueshima, Kazuomi, Isoda, Norio, Karino, Yoshiyasu, Kudo, Masatoshi, Tanaka, Katsuaki, Kaneko, Shuichi, Moriwaki, Hisataka, Makuuchi, Masatoshi, Okusaka, Takuji, Hayashi, Norio, Ohashi, Yasuo, Kumada, Hiromitsu, and The Peretinoin Study Group
- Published
- 2015
- Full Text
- View/download PDF
13. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study
- Author
-
Tateishi, Ryosuke, Okanoue, Takeshi, Fujiwara, Naoto, Okita, Kiwamu, Kiyosawa, Kendo, Omata, Masao, Kumada, Hiromitsu, Hayashi, Norio, and Koike, Kazuhiko
- Published
- 2015
- Full Text
- View/download PDF
14. Impact of bodyweight‐based starting doses on the safety and efficacy of lenvatinib in primarily Japanese patients with hepatocellular carcinoma.
- Author
-
Okusaka, Takuji, Kudo, Masatoshi, Ikeda, Kenji, Ikeda, Masafumi, Okita, Kiwamu, Sugawara, Michiko, Tamai, Toshiyuki, Ren, Min, Saito, Kenichi, and Kumada, Hiromitsu
- Subjects
JAPANESE people ,HEPATOCELLULAR carcinoma ,PATIENT safety ,OVERALL survival ,CONFIDENCE intervals - Abstract
Aim: The phase III REFLECT study utilized bodyweight‐based lenvatinib dosing in patients with unresectable hepatocellular carcinoma, based on results of the phase II Study 202. This post hoc analysis compared efficacy and safety in patients with lower and higher bodyweights. Methods: This comparison included patients from Study 202 (Japanese, n = 43; Korean, n = 3) and Japanese patients from REFLECT (n = 81) who received lenvatinib. In Study 202, all patients received a starting dose of lenvatinib 12 mg/day; in REFLECT, patients received starting doses based on bodyweight (patients <60 kg, 8 mg/day; ≥60 kg, 12 mg/day). Safety and efficacy were assessed in both studies according to bodyweight. Results: In Study 202, treatment‐related, treatment‐emergent adverse events (TEAEs) led to dose reductions in 80.8% and 55.0% of patients in the lower and higher bodyweight groups, respectively. In REFLECT, treatment‐related TEAEs led to dose reductions in 52.5% and 70.7% of patients in the 8 and 12 mg groups, respectively. In Study 202, median overall survival (OS) was 16.2 months (95% confidence interval [CI], 9.8–25.1) and 21.3 months (95% CI, 10.1–not estimable) in the lower and higher bodyweight groups, respectively. In REFLECT, median OS was 15.8 months (95% CI, 10.4–27.6) and 18.2 months (95% CI, 11.3–26.9) in the 8 and 12 mg groups, respectively. Conclusions: Comparison between patients in Study 202 and REFLECT demonstrates efficacy was maintained with improved safety in patients with lower bodyweights who received lenvatinib 8 mg/day in REFLECT versus patients who received lenvatinib 12 mg/day in Study 202. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study
- Author
-
Izumi, Namiki, Asahina, Yasuhiro, Kurosaki, Masayuki, Yamada, Gotaro, Kawai, Tsutomu, Kajiwara, Eiji, Okamura, Yukishige, Takeuchi, Takayuki, Yokosuka, Osamu, Kariyama, Kazuya, Toyoda, Joji, Inao, Mie, Tanaka, Eiji, Moriwaki, Hisataka, Adachi, Hiroshi, Katsushima, Shinji, Kudo, Masatoshi, Takaguchi, Kouichi, Hiasa, Yoichi, Chayama, Kazuaki, Yatsuhashi, Hiroshi, Oketani, Makoto, and Kumada, Hiromitsu
- Published
- 2013
- Full Text
- View/download PDF
16. Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma.
- Author
-
Kawamura, Yusuke, Kobayashi, Masahiro, Shindoh, Junichi, Matsumura, Masaru, Okubo, Satoshi, Muraishi, Nozomu, Fujiyama, Shunichiro, Hosaka, Tetsuya, Saitoh, Satoshi, Sezaki, Hitomi, Akuta, Norio, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Ikeda, Kenji, Arase, Yasuji, Hashimoto, Masaji, and Kumada, Hiromitsu
- Subjects
THERAPEUTIC use of monoclonal antibodies ,THERAPEUTIC use of antineoplastic agents ,PREOPERATIVE care ,DISEASE progression ,CONFIDENCE intervals ,MULTIVARIATE analysis ,TREATMENT effectiveness ,PROTEIN-tyrosine kinase inhibitors ,RADIOPHARMACEUTICALS ,POSITRON emission tomography ,SURVIVAL analysis (Biometry) ,DEOXY sugars ,BEVACIZUMAB ,PROGRESSION-free survival ,HEPATOCELLULAR carcinoma - Abstract
Background and Aims: The aim of this study was to identify the utility of
18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG-PET/CT) as a predictor of early progressive disease (e-PD) in patients with hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atezo/Bev). Methods: Twenty consecutive patients with measurable intrahepatic target nodules who received Atezo/Bev treatment were reviewed. The oncological aggressiveness of tumors estimated by18 F-FDG-PET/CT was analyzed using the rate of e-PD within 12 weeks and early progression-free survival (e-PFS) and overall survival (OS). Multivariate analysis was used to identify potential confounders for PD during Atezo/Bev therapy. Results: Using the Response Evaluation Criteria in Solid Tumors version 1.1, a tumor-to-normal liver ratio (TLR) ≥2, indicating higher oncological aggressiveness in HCCs, was associated with lower objective response rates compared with TLR values <2 (18% vs. 33%, respectively). Moreover, TLR values ≥2 were significantly associated with higher e-PD rates compared with TLR values <2 (64% vs. 11%, respectively) and worse e-PFS (p = 0.021). In multivariate analysis, TLR ≥2 showed marginal significance as a predictor of e-PD (p = 0.053), and utility as a predictor for worse e-PFS (hazard ratio, 7.153; 95% confidence interval, 1.258–40.689; p = 0.027). In contrast, no significant differences in OS with/without e-PD were observed during the treatment course. In this study, 8 patients experienced e-PD and almost 40% of patients experienced acceptable disease control following subsequent lenvatinib treatment. Conclusion: Pretreatment18 F-FDG-PET/CT may be a useful new predictor of e-PD and may enable early decision-making based on early treatment changes following Atezo/Bev treatment of HCC. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
17. Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus
- Author
-
Kobayashi, Masahiro, Ikeda, Kenji, Arase, Yasuji, Suzuki, Yoshiyuki, Suzuki, Fumitaka, Akuta, Norio, Hosaka, Tetsuya, Murashima, Naoya, Saitoh, Satoshi, Someya, Takashi, Tsubota, Akihito, and Kumada, Hiromitsu
- Published
- 2008
- Full Text
- View/download PDF
18. Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis
- Author
-
Someya, Takashi, Ikeda, Kenji, Saitoh, Satoshi, Kobayashi, Masahiro, Hosaka, Tetsuya, Sezaki, Hitomi, Akuta, Norio, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, and Kumada, Hiromitsu
- Published
- 2006
- Full Text
- View/download PDF
19. Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis
- Author
-
Ikeda, Kenji, Arase, Yasuji, Kobayashi, Masahiro, Saitoh, Satoshi, Someya, Takashi, Hosaka, Tetsuya, Suzuki, Yoshiyuki, Suzuki, Fumitaka, Tsubota, Akihito, Akuta, Norio, and Kumada, Hiromitsu
- Published
- 2003
- Full Text
- View/download PDF
20. Ultrasensitive Assay for Hepatitis B Core‐Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir.
- Author
-
Hosaka, Tetsuya, Suzuki, Fumitaka, Kobayashi, Mariko, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Akuta, Norio, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu
- Subjects
CHRONIC hepatitis B ,HEPATITIS associated antigen ,HEPATITIS B ,HEPATOCELLULAR carcinoma ,CIRCULAR DNA ,CELL surface antigens ,BIOMARKERS - Abstract
Serum hepatitis B core‐related antigen (HBcrAg) and surface antigen (HBsAg) are surrogate markers of intrahepatic covalently closed circular DNA. The measurement range of the current HBcrAg assay is relatively narrow. Thus, we examined the potential of HBcrAg and HBsAg measured by ultrasensitive assays for predicting hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B treated with entecavir (ETV). We conducted a retrospective cohort study of 180 patients who received ETV for >1 year. All patients had hepatitis B e‐antigen negativity at baseline. Serum HBcrAg and HBsAg levels at baseline and year 1 were measured in all patients by ultrasensitive assays using immunoassay for total antigen including complex by pretreatment (iTACT) technology. During the median follow‐up of 11.0 years, 22 patients developed HCC (11.8/1,000 person‐years). Baseline HBsAg levels were not associated with HCC development during ETV treatment. However, high HBcrAg levels at baseline and at year 1 were significantly associated with HCC development (log‐rank test; P < 0.001). In 110 patients (61.1%) with ≥4.0 log U/mL at baseline (high HBcrAg cohort), HBcrAg declined to ≤2.9 log U/mL at year 1 in 25 patients (22.7%). The adjusted hazard ratio for HCC incidence was significantly lower in patients with HBcrAg ≤2.9 log U/mL at year 1 than in those in the high HBcrAg cohort. Conclusion: Measurement of HBcrAg by ultrasensitive assay has better potential for predicting HCC during antiviral treatment than the current HBcrAg assay. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib Treatment.
- Author
-
Kawamura, Yusuke, Kobayashi, Masahiro, Shindoh, Junichi, Kobayashi, Yuta, Okubo, Satoshi, Muraishi, Nozomu, Iritani, Soichi, Fujiyama, Shunichiro, Hosaka, Tetsuya, Saitoh, Satoshi, Sezaki, Hitomi, Akuta, Norio, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Ikeda, Kenji, Arase, Yasuji, Hashimoto, Masaji, and Kumada, Hiromitsu
- Subjects
SURVIVAL ,MULTIVARIATE analysis ,PROTEIN-tyrosine kinase inhibitors ,COMPARATIVE studies ,RADIOPHARMACEUTICALS ,DESCRIPTIVE statistics ,DEOXY sugars ,HEPATOCELLULAR carcinoma - Abstract
Background and Aim: The aim of this study was to identify the utility of
18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG-PET/CT) as a predictor of overall prognosis in patients with hepatocellular carcinoma treated with lenvatinib. Methods: Forty-eight consecutive patients who received lenvatinib treatment were reviewed. The oncological aggressiveness of tumors estimated using18 F-FDG-PET/CT was investigated by the analysis of progression-free survival (PFS), post-progression survival (PPS), and overall survival (OS). Multivariate analysis was used to identify potential confounders for OS during lenvatinib therapy. Results: Using the Modified Response Evaluation Criteria in Solid Tumors, a tumor-to-normal liver ratio (TLR) ≥2, indicating higher oncological aggressiveness in HCCs, was associated with a better objective response to lenvatinib than a TLR <2 (78 vs. 62%), resulting in a similar PFS (p = 0.751). Because of a significantly worse PPS, OS with a TLR ≥2 was poor compared to a TLR < 2 (p = 0.012). Multivariate analysis confirmed that a TLR ≥ 2 was associated with poor OS (hazard ratio, 2.709; 95% CI, 1.140–6.436; p = 0.024). Analysis of 24 patients who received a repeat18 F-FDG-PET/CT showed that daily changes expressed as ΔTLR × 103 /day over the treatment course tended to be different among the types of subsequent treatment. A R0 resection and lenvatinib-TACE sequential therapy provided good disease control (median, −4.593 and −0.024, respectively) compared with other treatments (median, 5.278) (p = 0.075). Conclusion: Lenvatinib has acceptable disease control regardless of estimated tumor differentiation. A high TLR (≥2) is a poor prognostic factor of OS following lenvatinib treatment, while ΔTLR × 103 /day provides useful information of disease control status. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
22. Potential of ultra‐highly sensitive immunoassays for hepatitis B surface and core‐related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
- Author
-
Suzuki, Fumitaka, Hosaka, Tetsuya, Imaizumi, Masayasu, Kobayashi, Mariko, Ohue, Chiharu, Suzuki, Yoshiyuki, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Akuta, Norio, Kobayashi, Masahiro, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu
- Subjects
HEPATITIS associated antigen ,HEPATOCELLULAR carcinoma ,RECEIVER operating characteristic curves ,CHRONIC hepatitis B ,IMMUNOASSAY - Abstract
Aims: Hepatitis B surface antigen (HBsAg) seroclearance indicates a "functional cure" in chronic hepatitis B (CHB) virus infection. However, several cases of hepatocellular carcinoma (HCC) development have been reported after HBsAg seroclearance. We evaluated the potential of HBsAg and hepatitis B core‐related antigen (HBcrAg), measured by the ultra‐highly sensitive assays, in cases with HCC development after HBsAg seroclearance. Methods: We enrolled 17 patients with CHB who achieved HBsAg seroclearance, defined by the conventional assay using Architect HBsAg QT kit (five HCC patients and 12 non‐HCC patients). HBsAg and HBcrAg were measured in their stored serum samples using ultra‐highly sensitive assays featuring "immunoassay for total antigen including complex via pretreatment (iTACT)" technology. Results: All five patients who developed HCC were positive for HBsAg or HBcrAg by iTACT‐HBsAg or iTACT‐HBcrAg at all follow‐up points. HBcrAg levels in the HCC group, using iTACT‐HBcrAg, were significantly higher than those in the non‐HCC group at HBsAg seroclearance (3.6 LogU/ml (2.8–4.2) versus 2.6 (<2.1–3.8), p = 0.020). The best cutoff value of iTACT‐HBcrAg for predicting HCC development was 2.7 LogU/ml by receiver operating characteristic curve analysis. The prevalence of HBcrAg ≥2.7 in the HCC group was significantly higher than that in non‐HCC group (100% [5/5] versus 33% [4/12], p = 0.029). Conclusions: Residual low viral antigen might predict HCC development even if HBsAg seroclearance was achieved according to a conventional assay. The results suggest that iTACT assays of HBsAg and HBcrAg would be useful for monitoring CHB patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.
- Author
-
Yamashige, Daiki, Kawamura, Yusuke, Kobayashi, Masahiro, Shindoh, Junichi, Kobayashi, Yuta, Okubo, Satoshi, Muraishi, Nozomu, Kajiwara, Akira, Iritani, Soichi, Fujiyama, Shunichiro, Hosaka, Tetsuya, Saitoh, Satoshi, Sezaki, Hitomi, Akuta, Norio, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Ikeda, Kenji, Arase, Yasuji, Hashimoto, Masaji, and Kumada, Hiromitsu
- Subjects
ALPHA fetoproteins ,MAGNETIC resonance imaging ,PROTEIN-tyrosine kinase inhibitors ,RADIOPHARMACEUTICALS ,POSITRON emission tomography ,DESCRIPTIVE statistics ,DEOXY sugars ,COMPUTED tomography ,HEPATOCELLULAR carcinoma - Abstract
Background: The sensitivity of
18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG-PET/CT) in hepatocellular carcinoma (HCC) is low; however, clinical evidence demonstrating its prognostic value in patients with HCC has recently been reported. This study aimed to assess the value of18 F-FDG-PET/CT as a tool for evaluating the response of HCC to lenvatinib treatment. Methods: We evaluated 11 consecutive patients with HCC diagnosed by dynamic CT or magnetic resonance imaging combined with18 F-FDG-PET/CT from April 2018 to December 2019. The tumor-to-normal liver ratio (TLR) of the target tumor was measured before and during the course of lenvatinib treatment with18 F-FDG-PET/CT (pre and post analysis, respectively), with a TLR ≥2 classified as PET-positive HCC. At the time of each evaluation, we also used the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, the modified RECIST (mRECIST), and the tumor marker alfa-fetoprotein (AFP). Results: Of 11 patients, 3 (27%) and 8 (73%) had an objective response to lenvatinib treatment at the time of post-analysis by RECIST 1.1 and mRECIST, respectively. There were 3 (27%) and 7 (64%) patients with PET-positive HCC at the time of pre- and post-analysis, respectively. There was a significant correlation between the rates of change in AFP and TLR during lenvatinib treatment (r = 0.69, p = 0.019). Based on these results, we were able to perform liver resection on 4 patients with PET-positive HCC as conversion therapy. Three samples from these patients showed poorly differentiated tumors. Conclusion:18 F-FDG-PET/CT has potential as an evaluation tool for describing biological tumor behavior and reflecting disease progression, location, and treatment response. This modality may provide useful information for considering prognosis and subsequent therapy. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
24. TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
- Author
-
Akuta, Norio, Kawamura, Yusuke, Kobayashi, Mariko, Arase, Yasuji, Saitoh, Satoshi, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Suzuki, Fumitaka, Ikeda, Kenji, and Kumada, Hiromitsu
- Subjects
EXTRACELLULAR space ,NON-alcoholic fatty liver disease ,HEPATOCELLULAR carcinoma ,MULTIVARIATE analysis ,GENETIC mutation ,NUCLEIC acids ,TRANSFERASES ,TUMOR markers ,TELOMERASE ,PREDICTIVE validity ,PREDICTIVE tests ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,BLOOD - Abstract
Introduction: It remains unclear whether TERT promoter mutation (TERT C228T) in serum cell-free DNA (cfDNA) is useful for the diagnosis of hepatocellular carcinoma (HCC) in patients with nonalcoholic fatty liver disease (NAFLD). Methods: In this retrospective study, we analyzed the relationships between TERT C228T in serum cfDNA and levels of AFP and PIVKAII in 57 Japanese patients with histopathologically confirmed NAFLD background, consisting of 36 patients with HCC and 21 without HCC. We also examined the liver-related survival rate and HCC recurrence rate after the initial treatment for HCC. TERT C228T was detected using a highly sensitive method based on wild-type blocking PCR (detection limit in excess of 0.7% mutant-type DNA). Results: In all of the 57 patients, multivariate analysis identified TERT C228T positive as significant determinant of primary HCC. In the 36 patients with HCC, the percentage of patients positive for TERT C228T was 63.9%. The percentage of patients positive for TERT C228T with normal AFP and PIVKAII was 35.3%. The positive predictive value and specificity for prediction of BCLC stage 0 or A were both high. In 6 patients, TERT C228T was repeatedly negative during follow-up but became positive at the time of HCC diagnosis. Four patients who underwent HCC surgical resection had well-differentiated solitary HCC measuring <30 mm, and all were TERT C228T positive with normal AFP and PIVKAII. TERT C228T status had no influence on the cumulative liver-related survival rate and HCC recurrence rate. Conclusions: Our results highlight the superiority of TERT C228T in serum cfDNA compared with AFP and PIVKAII in the early diagnosis of primary HCC in NAFLD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease.
- Author
-
Ochiai, Yorinari, Kawamura, Yusuke, Kobayashi, Masahiro, Shindoh, Junichi, Kobayashi, Yuta, Okubo, Satoshi, Muraishi, Nozomu, Kajiwara, Akira, Iritani, Soichi, Fujiyama, Shunichiro, Hosaka, Tetsuya, Saitoh, Satoshi, Sezaki, Hitomi, Akuta, Norio, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Ikeda, Kenji, Arase, Yasuji, Hashimoto, Masaji, and Kumada, Hiromitsu
- Subjects
FATTY liver ,ALCOHOL drinking ,ALCOHOLIC liver diseases ,LIVER histology - Abstract
Aim: The number of patients with fatty liver disease (FLD) is increasing globally. Ethanol consumption in FLD is known to be associated with an increased risk of hepatocellular carcinoma (HCC), but the effects of alcohol consumption on the occurrence of multiple HCCs remain unclear. We explored the relationship between the daily ethanol intake and the HCC number. Methods: This single‐center retrospective study enrolled 114 patients without viral or immune hepatitis undergoing first‐line HCC treatment who had been diagnosed with FLD by abdominal ultrasonography or a liver biopsy at the same time as or before HCC detection. We categorized patients into four groups according to the daily alcohol consumption (<20 g: non‐alcoholic fatty liver disease, n = 45; 20–39 g: low‐intermediate ethanol intake with FLD, n = 13; 40–69 g: high‐intermediate ethanol intake with FLD, n = 31; ≥70 g: alcoholic fatty liver disease, n = 25). The relationship between the daily ethanol consumption and the number of HCCs (single or multiple) was examined. Results: The risk of multiple HCCs was significantly higher in the high‐intermediate ethanol intake with FLD (HR 2.89, 95% CI 1.04–8.02, P = 0.042) and alcoholic fatty liver disease (HR 3.14, 95% CI 1.07–9.22, P = 0.037) groups than in the others. A multivariate analysis showed that a daily ethanol intake ≥40 g was associated with a significantly increased risk of multiple HCCs (HR 2.82, 95% CI 1.16–6.88, P = 0.023). Conclusions: Our findings suggest that a high daily ethanol intake might lead to multiple hepatocarcinogenesis in patients with FLD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. Detection of TERT promoter mutation in serum cell‐free DNA using wild‐type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma.
- Author
-
Akuta, Norio, Suzuki, Fumitaka, Kobayashi, Mariko, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Suzuki, Yoshiyuki, and Kumada, Hiromitsu
- Subjects
TELOMERASE reverse transcriptase ,DNA ,CELL-free DNA ,PROMOTERS (Genetics) ,SOMATIC mutation ,BLOCKCHAINS ,POLYMERASE chain reaction - Abstract
Telomerase reverse transcriptase (TERT) promoter mutation is the most frequent genetic alteration in hepatocellular carcinoma (HCC). However, there is currently no suitable highly sensitive method that can detect such mutation using serum cell‐free DNA (cfDNA). We analyzed somatic point mutations that substitute cytosine for thymidine at position 228 (C228T), as one of the hotspots of TERT promoter mutations, in serum cfDNA using a highly sensitive detection method of wild‐type blocking polymerase chain reaction (WTB‐PCR) combined with Sanger sequencing. In TERT promoter mutation sensitivity study, synthetic oligonucleotides were prepared to determine the lowest detection limit of the WTB‐PCR, using serial dilutions of mutant‐type (MT) DNA in the background of wild‐type (WT) DNA. Using this technique, we conducted a longitudinal study in one patient who developed HCC during the follow‐up and determined the relationship between HCC and TERT C228T in serum cfDNA. In the sensitivity study, the mutant peak at position 228 was detected at 0.7% or higher but was not detected at 0.6%. Thus, sequencing analysis of WTB‐PCR product demonstrated the limit of detection in excess of 0.7% MT DNA in the background of WT DNA. One male patient with HCV‐related cirrhosis developed HCC during the follow‐up. TERT C228T was negative before the diagnosis of HCC, positive at the diagnosis of HCC and did not increase with advancement of malignancy. We developed a highly sensitive method for detection of TERT promoter mutation using WTB‐PCR combined with Sanger sequencing and demonstrated its clinical usefulness in the measurement of TERT C228T in serum cfDNA. Larger studies are needed to confirm these results and establish the clinical utility of this new method. Research Highlights: We developed a highly sensitive method for detection of TERT promoter mutation using WTB‐PCR combined with Sanger sequencing and demonstrated its clinical usefulness in the measurement of TERT C228T in serum cfDNA. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
27. Advantage of liver stiffness measurement before and after direct‐acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C.
- Author
-
Ogasawara, Nobuhiko, Saitoh, Satoshi, Akuta, Norio, Sezaki, Hitomi, Suzuki, Fumitaka, Fujiyama, Shunichiro, Kawamura, Yusuke, Hosaka, Tetsuya, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu
- Subjects
CHRONIC hepatitis C ,ESOPHAGEAL varices ,HEPATOCELLULAR carcinoma ,CIRRHOSIS of the liver ,LIVER - Abstract
Aim: The risk of development of hepatocellular carcinoma (HCC) persisted in patients with advanced fibrosis, even after achieving sustained virologic response (SVR). This study aimed to show the advantage of liver stiffness measurement (LSM) at baseline and after SVR to predict HCC occurrence and esophageal varices (EV) exacerbation. Methods: These risks were evaluated in 398 chronic hepatitis C patients without a history of HCC who achieved SVR after direct‐acting antiviral agent and evaluated LSM at least twice during follow up. We defined liver cirrhosis and chronic hepatitis as LSM of ≥12 kPa and <12 kPa, respectively. Results: LSM was significantly correlated with serum fibrosis markers, such as Fib‐4 index and Wisteria floribunda agglutinin‐positive Mac‐2 binding protein, at baseline and SVR at 24 weeks after treatment (SVR24). Five patients received preventive treatment of EV, but no EV bleeding occurred after SVR, and their LSM at baseline and SVR24 was significantly higher than that of other cirrhosis patients. The annual rate of HCC during the first 4 years was 1.5%. LSM in HCC patients tended to decrease after direct‐acting antiviral agent therapies, but significantly higher than that of cirrhosis patients without HCC before and after treatment. Multivariate analysis identified LSM and alpha‐fetoprotein at baseline and LSM at SVR24 as significant independent predictors of HCC. Conclusions: Evaluating LSM not only at baseline, but also SVR24, was found to be useful for the detection of advanced fibrosis patients at high risk of HCC occurrence and EV exacerbation. We recommend focused surveillance of HCC and EV for these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
28. Long‐term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus‐related liver cirrhosis after interferon‐based therapy.
- Author
-
Ogasawara, Nobuhiko, Saitoh, Satoshi, Akuta, Norio, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu
- Subjects
ESOPHAGEAL varices ,CIRRHOSIS of the liver ,HEPATOCELLULAR carcinoma ,HEPATITIS C virus ,MORTALITY ,HEPATITIS - Abstract
Aim: The long‐term effects of sustained virologic response (SVR) to antiviral therapy on the risk of liver complications, such as exacerbation of esophageal varices (EV), hepatocellular carcinoma (HCC), malignant lymphoma, and liver‐related and overall death in hepatitis C virus (HCV)‐infected patients with liver cirrhosis are not fully known. Methods: These risks were evaluated during long‐term follow up of 457 patients with HCV‐related Child–Pugh Class A liver cirrhosis without history of HCC. Results: The respective cumulative 5‐ and 10‐year rates of EV exacerbation were 2.0% and 3.1%. Multivariate analysis identified the presence of EVs, thrombocytopenia at baseline. and alcohol intake as significant independent predictors of EV exacerbation before and after SVR. The cumulative 5‐ and 10‐year rates of HCC were 6.8% and 10.2%, respectively. Male sex and the presence of EV were significant independent determinants of HCC before and after SVR. Although the cumulative 5‐year HCC recurrence rate was 49.4%, the overall survival rate since HCC was 73.6% at 5 years. The overall survival rates since SVR were 98.7% and 93.6% at 5 and 10 years, respectively. Progression of HCC was the most frequent all‐cause mortality, but none of the patients died of liver decompensation. Male sex and Fibrosis‐4 index of ≥3.0 after SVR were significant and independent predictors of mortality. Conclusion: Patients with HCV remain at risk of HCC for >10 years after achieving SVR, and HCC is the most common cause of mortality. We recommend long‐term surveillance of cirrhotic patients with HCV, even after achieving SVR. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
29. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
- Author
-
Suzuki, Fumitaka, Hosaka, Tetsuya, Suzuki, Yoshiyuki, Sezaki, Hitomi, Akuta, Norio, Fujiyama, Shunichiro, Kawamura, Yusuke, Kobayashi, Masahiro, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Kobayashi, Mariko, Mineta, Rie, Suzuki, Yukiko, and Kumada, Hiromitsu
- Subjects
CHRONIC hepatitis B ,HEPATITIS B ,ALANINE aminotransferase ,HEPATITIS associated antigen ,HEPATITIS B virus ,ANTIVIRAL agents ,DNA ,DRUG resistance in microorganisms ,HEPATITIS viruses ,HEPATOCELLULAR carcinoma ,LIVER tumors ,LONGITUDINAL method ,PURINES ,TIME ,VIRAL antigens ,TREATMENT effectiveness ,GENOTYPES ,DISEASE complications - Abstract
Background: We determined the antiviral potency and viral breakthrough rate after 10 years of continuous entecavir treatment in patients with chronic hepatitis B (CHB) infection.Methods: The cumulative rates of undetectable hepatitis B virus DNA (HBV-DNA, < 2.1 log copies/mL), alanine aminotransferase (ALT) normalization, hepatitis B e antigen (HBeAg) seroclearance, hepatitis B surface antigen (HBsAg) seroclearance, and viral breakthrough of 1094 nucleos(t)ide analogue-naïve CHB patients (HBeAg-positive: 47%) who were on continuous entecavir treatment for 10 years were calculated.Results: The median age was 50 years and follow-up period was 5.5 years, with 999, 804, 591, 390, 182 and 87 patients followed up for at least 1, 3, 5, 7, 9 and 10 years, respectively. Incremental increases were noted in the rates of undetectable HBV-DNA, ALT normalization, HBeAg seroclearance, and HBsAg seroclearance, reaching 96, 79, 38 and 3.7%, respectively, by the tenth year. The mean decline in HBsAg level from baseline was - 0.08 log IU/mL/year. Multivariate analysis identified HBsAg level and genotype (A) as independent predictors of HBsAg seroclearance. Sixteen patients experienced viral breakthrough. The cumulative percentages of patients with viral breakthrough analyzed by the Kaplan-Meier test were 1.5 and 2.5% at years 5 and 10, respectively. There were no serious adverse events during treatment.Conclusions: Long-term entecavir treatment of nucleos(t)ide analogue-naïve CHB patients was associated with an excellent viral response and a low rate of entecavir-resistant mutations at 10 years. Baseline HBsAg levels and genotype were predictors of HBsAg seroclearance during entecavir treatment. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
30. No‐touch ablation in hepatocellular carcinoma has the potential to prevent intrasubsegmental recurrence to the same degree as surgical resection.
- Author
-
Kawamura, Yusuke, Ikeda, Kenji, Shindoh, Junichi, Kobayashi, Yuta, Kasuya, Kayoko, Fujiyama, Shunichiro, Hosaka, Tetsuya, Kobayashi, Masahiro, Saitoh, Satoshi, Sezaki, Hitomi, Akuta, Norio, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, Hashimoto, Masaji, and Kumada, Hiromitsu
- Subjects
THERAPEUTIC touch ,LIVER cancer ,CATHETER ablation ,MAGNETIC resonance imaging ,SERUM ,COMPUTED tomography - Abstract
Aim: The aim of this study was to clarify the utility of a no‐touch pincer ablation procedure that uses bipolar electrodes to prevent intrasubsegmental tumor recurrence after radiofrequency ablation (RFA) for patients with hepatocellular carcinoma (HCC) compared to surgical resection. Methods: We evaluated 175 consecutive patients with HCC (single nodule, tumor diameter ≤ 30 mm) who underwent surgical resection (146 received partial resection) and 313 patients who received RFA; 277 patients received touch ablation using a monopolar or bipolar RFA device, and 36 received no‐touch ablation using a bipolar RFA device. Pretreatment arterial and portal phase dynamic computed tomography (CT) or magnetic resonance imaging (MRI) images were classified into four enhancement patterns: Type 1 and Type 2 are homogeneous enhancement patterns without or with increased arterial blood flow, respectively; Type 3 is a heterogeneous enhancement pattern with a septum‐like structure; and Type 4 is an irregularly shaped ring structure enhancement pattern. Results: Cumulative recurrence rates significantly differed between procedures (surgical resection, 7.5%; no‐touch ablation, 2.9%; and touch ablation, 17.7% at the third year; P = 0.005). Multivariate Cox proportional hazards analysis revealed that enhancement pattern type (Type 3: hazard ratio [HR], 2.95; P = 0.002; and Type 4: HR, 3.88, P = 0.002), treatment procedure (touch ablation: HR, 3.36; P < 0.001), and serum α‐fetoprotein level (≥30 μg/L: HR, 1.87; P = 0.009) were significant predictors of intrasubsegmental recurrence. No significant differences between no‐touch ablation and surgical resection were observed. Conclusion: The no‐touch pincer ablation procedure has the potential to prevent intrasubsegmental recurrence after RFA for patients with HCC to the same degree as partial resection. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
31. Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all‐oral direct‐acting antiviral regimens.
- Author
-
Ogata, Fumihiro, Akuta, Norio, Kobayashi, Masahiro, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Mariko, Saitoh, Satoshi, Suzuki, Yoshiyuki, Suzuki, Fumitaka, Arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu
- Abstract
Impact of substitution of aa70 in the core region (Core aa70) in HCV genotype 1b (HCV‐1b) on hepatocarcinogenesis following eradication of HCV RNA by direct‐acting antiviral therapy is not clear. In a retrospective study, 533 patients with HCV‐related chronic liver disease, with sustained virological response defined as negative HCV RNA at 12 weeks after cessation of direct‐acting antiviral therapy, were examined to evaluate the relationship between Core aa70 substitution and hepatocarcinogenesis. Twelve patients developed hepatocellular carcinoma during the follow‐up period. The cumulative hepatocarcinogenesis rates were 1.7% and 2.4% at the end of 1 and 2 years, respectively. Overall, multivariate analysis identified HCV subgroup (HCV‐1b with Gln70(His70);
P = 0.003) and age (>65 years;P = 0.049), as pretreatment predictors of hepatocarcinogenesis. In HCV‐1b patients, multivariate analysis identified post‐treatmentWisteria floribunda agglutinin positive Mac‐2 binding protein (>1.8 COI;P = 0.042) and HCV subgroup (HCV‐1b with Gln70(His70);P = 0.071), as predictors of hepatocarcinogenesis, including post‐treatment parameter. In conclusion, Core aa70 substitution in HCV‐1b at the start of direct‐acting antiviral therapy is an important predictor of hepatocarcinogenesis following eradication of HCV RNA. This study emphasizes the importance of detection of Core aa70 substitution before initiating antiviral therapy. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
32. Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimens.
- Author
-
Reddy, K. Rajender, Pol, Stanislas, Thuluvath, Paul J., Kumada, Hiromitsu, Toyota, Joji, Chayama, Kazuaki, Levin, James, Lawitz, Eric J., Gadano, Adrian, Ghesquiere, Wayne, Gerken, Guido, Brunetto, Maurizia R., Peng, Cheng‐yuan, Silva, Marcelo, Strasser, Simone I., Heo, Jeong, Mcphee, Fiona, Liu, Zhaohui, Yang, Rong, and Linaberry, Misti
- Subjects
CLINICAL trials ,HEPATITIS C virus ,DRUG efficacy ,INTERFERONS ,LIVER cancer - Abstract
Abstract: Background & Aims: Daclatasvir has achieved high sustained virologic response (SVR) rates in diverse hepatitis C virus (HCV) populations. This study evaluated the long‐term efficacy and safety of daclatasvir‐based regimens administered during clinical studies. Methods: Patients enrolled within 6 months of parent study completion or protocol availability at the study sites. The primary objective was durability of SVR at follow‐up Week 12 (SVR12). Secondary objectives included analysing HCV sequences in non‐responders or responders who relapsed, and characterization of liver disease progression. Results: Between 24 February 2012 and 17 July 2015, this study enrolled and began following 1503 recipients of daclatasvir‐based regimens (follow‐up cut‐off, 13 October 2015); 60% were male, 18% aged ≥65 years, 87% had genotype‐1a (42%) or ‐1b (45%) infection, and 18% had cirrhosis. Median follow‐up from parent study follow‐up Week 12 was 111 (range, 11‐246) weeks. 1329/1489 evaluable patients were SVR12 responders; 1316/1329 maintained SVR until their latest visit. Twelve responders relapsed by (n = 9) or after (n = 3) parent study follow‐up Week 24; one was reinfected. Relapse occurred in 3/842 (0.4%) and 9/487 (2%) responders treated with interferon‐free or interferon‐containing regimens, respectively. Hepatic disease progression and new hepatocellular carcinoma were diagnosed in 15 and 23 patients, respectively. Among non‐responders, emergent non‐structural protein‐5A (NS5A) and ‐3 (NS3) substitutions were replaced by wild‐type sequences in 27/157 (17%) and 35/47 (74%) patients, respectively. Conclusions: SVR12 was durable in 99% of recipients of daclatasvir‐based regimens. Hepatic disease progression and new hepatocellular carcinoma were infrequent. Emergent NS5A substitutions persisted longer than NS3 substitutions among non‐responders. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
33. Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride.
- Author
-
Akuta, Norio, Kumada, Hiromitsu, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, Suzuki, Yoshiyuki, Suzuki, Fumitaka, Arase, Yasuji, and Ikeda, Kenji
- Subjects
- *
ITCHING , *LIVER disease treatment , *LIVER diseases , *MULTIVARIATE analysis , *LIVER cancer , *PATIENTS , *THERAPEUTICS - Abstract
Aim Pruritus is one of the complications of chronic liver disease, and it is important to investigate the predictors. Methods Six hundred and seventy-three consecutive Japanese patients with chronic liver disease were retrospectively investigated for itch severity. Furthermore, 138 of all 673 patients were introduced to nalfurafine hydrochloride, and the improvement of itch severity was evaluated. The itch severity was self-assessed using the pruritus scores by Kawashima's criteria and visual analog scale. Results Two hundred and twenty-nine of the 673 patients (34.0%) were evaluated as 1 point or more of pruritus severity of Kawashima's criteria, and 46 patients (6.8 %) as 3 points or more. Multivariate analysis established that being negative for hepatitis B surface antigen (HBsAg) and presence of hepatocellular carcinoma (HCC) were significant determinants of pruritus (≥1 point of Kawashima's criteria), and being negative for HBsAg and having lower levels of platelet count were significant determinants of severe pruritus (≥3 points). Ninety-three of the 138 patients (67.4%) with nalfurafine hydrochloride indicated improvement of itch, defined as a decrease in VAS of 50 mm or more. There were no significant differences in treatment efficacy of nalfurafine hydrochloride, regardless of the three predictors of pruritus (HBsAg, HCC and platelet count). Conclusion The present retrospective study indicated the predictors for pruritus, based on the large number of patients with chronic liver disease. Furthermore, this study demonstrated that nalfurafine hydrochloride may be useful for pruritus, regardless of the predictors. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
34. Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus.
- Author
-
Osawa, Mitsutaka, Akuta, Norio, Suzuki, Fumitaka, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, Arase, Yasuji, Suzuki, Yoshiyuki, Ikeda, Kenji, and Kumada, Hiromitsu
- Abstract
With rapidly aging population in the world, many elderly patients present with hepatitis B virus (HBV) infection. We conducted a retrospective cohort study involving 359 untreated HBV patients aged 60 and older who were free of hepatocellular carcinoma (HCC) and acute hepatitis at the initial visit, and examined the incidence of HCC and liver-related mortality rate. During the follow-up period of 7.9 years (range, 0-25 years), 26 patients (7.2% of patients) developed HCC, 20 patients died from liver-related diseases (61% of total deaths), including HCC, liver failure, and gastrointestinal bleeding. The cumulative rates of HCC at years 5, 10, and 15 were 6.5%, 15.6%, and 15.6%, respectively. The cumulative rates of mortality from liver-related diseases at years 5, 10, 15 were 3.3%, 12.3%, and 15.7%, respectively. Multivariate analysis identified HBV DNA (≥5.0 Log IU/mL), male gender, and FIB4-Index (≥3.6) as significant independent risk factors for HCC, and alpha-fetoprotein (≥10 ng/mL) as significant independent predictors of liver-related mortality. We conclude that high levels of HBV DNA, progression of liver fibrosis, and male gender are independent risk factors of HCC in untreated patients infected with HBV aged 60 and older. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
35. Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.
- Author
-
Ikeda, Kenji, Kawamura, Yusuke, Kobayashi, Masahiro, Kominami, Yoko, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Akuta, Norio, Saitoh, Satoshi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, and Kumada, Hiromitsu
- Subjects
LIVER cancer ,ANTIVIRAL agents ,SURGERY ,CATHETER ablation ,DISEASE relapse ,HEPATITIS C diagnosis ,TUMOR treatment ,CANCER relapse ,COMPARATIVE studies ,DRUG administration ,HEPATECTOMY ,HEPATITIS C ,HEPATOCELLULAR carcinoma ,LIVER tumors ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,TIME ,TUMOR classification ,EVALUATION research ,TREATMENT effectiveness ,PROPORTIONAL hazards models ,RETROSPECTIVE studies ,KAPLAN-Meier estimator ,CHEMOEMBOLIZATION ,DISEASE complications ,THERAPEUTICS - Abstract
Background: Suppressive activity of recurrence by interferon-free direct-acting antivirals (DAA) is not elucidated after curative treatment of hepatocellular carcinoma (HCC).Patients and Methods: A total of 177 patients received DAA after curative manners of HCC: 89 patients underwent DAA therapy after initial HCC treatment, and the other 88 patients after repeated therapy of 2-10 times. Among a cohort of HCC patients with surgery and radiofrequency ablation, 89 patients were chosen adjusting age, gender, and Barcelona Clinic Liver Cancer (BCLC) staging with 89 patients with initial HCC therapy.Results: HCC recurrence rates at the end of first and second year were 18.1 and 22.1% in patients with once of HCC therapy, 28.2 and 41.6% in those with 2-3 times of therapy, and 60.2 and 74.5% in those with 4 or more times of therapy, respectively (P < 0.0001). Recurrence rates were compared between 89 patients with DAA therapy after initial HCC therapy and 89 age-, gender-, and BCLC staging-matched patients without antiviral therapy after initial HCC therapy. HCC recurrence rates at first and second year were 18.1 and 25.0% in patients with DAA therapy and 21.8 and 46.5% in those without DAA therapy, respectively (P = 0.003). Multivariate analysis showed DAA therapy significantly decreased recurrence rate with a hazard ratio of 0.353 (confidence interval: 0.191-0.651) after adjustment with covariates of tumor multiplicity, alpha-fetoprotein value, and prothrombin time.Conclusions: DAA therapy significantly decreased recurrence rate when it was performed after initial HCC therapy. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
36. Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses.
- Author
-
Tamai, Toshiyuki, Hayato, Seiichi, Hojo, Seiichiro, Suzuki, Takuya, Okusaka, Takuji, Ikeda, Kenji, and Kumada, Hiromitsu
- Subjects
EVALUATION of clinical trials ,CIRRHOSIS of the liver ,ALKALINE phosphatase ,BODY weight ,CANCER patients ,DRUG side effects ,HEPATOCELLULAR carcinoma ,LIVER function tests ,EVALUATION of medical care ,PHARMACEUTICAL arithmetic ,PHARMACOKINETICS ,RESEARCH funding ,DRUG development ,DISEASE relapse ,LOGISTIC regression analysis ,PROTEIN-tyrosine kinase inhibitors ,DRUG approval ,TERMINATION of treatment ,ALBUMINS ,TREATMENT effectiveness ,CONTROL groups ,ACQUISITION of data ,DATA analysis software ,DIAGNOSIS ,THERAPEUTICS - Abstract
Hepatocellular carcinoma (HCC) accounts for up to 90% of primary liver cancer occurrences worldwide. Lenvatinib, a multikinase inhibitor, was approved in radioiodine-refractory differentiated thyroid cancer. In this phase 2 study (study 202), we aimed to identify the lenvatinib optimal dose for subjects with advanced HCC Child-Pugh class A. Pooled data from phase 1 studies in healthy adults and in subjects with mixed tumor types, and from study 202 in subjects with HCC, were analyzed using a population pharmacokinetic approach. The relationship between treatment-emergent adverse events leading to withdrawal or dose reduction during cycle 1 and lenvatinib exposure was explored by logistic regression analysis. A receiver operating characteristics analysis was used to investigate the best cutoff values of lenvatinib exposure and body weight to identify a high-risk group for early dose modification. The final pharmacokinetic model included body-weight effects on apparent clearance and volume. The relationship between the lenvatinib area under the plasma concentration-time curve (AUC) at steady state and body weight demonstrated an increase in AUC as body weight decreased in subjects with HCC. An exposure-response relationship was observed, with higher lenvatinib AUC and lower body weight resulting in earlier drug withdrawal or dose reduction. The best cutoff values for body weight and lenvatinib AUC were 57.8 kg and 2430 ng·h/mL, respectively, to predict the group at high risk for early drug withdrawal or dose reduction. We therefore recommend 12-mg and 8-mg starting doses for subjects ≥60 kg and <60 kg, respectively, in subjects with HCC Child-Pugh class A. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
37. Potential of a no-touch pincer ablation procedure that uses a multipolar radiofrequency ablation system to prevent intrasubsegmental recurrence of small and single hepatocellular carcinomas.
- Author
-
Kawamura, Yusuke, Ikeda, Kenji, Fujiyama, Shunichiro, Hosaka, Tetsuya, Kobayashi, Masahiro, Saitoh, Satoshi, Sezaki, Hitomi, Akuta, Norio, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, and Kumada, Hiromitsu
- Subjects
LIVER cancer ,MAGNETIC resonance imaging of cancer ,BLOOD flow measurement ,CANCER relapse ,CATHETER ablation - Abstract
Objective The aim of this study was to clarify the usefulness of a no-touch pincer ablation procedure that uses bipolar electrodes to prevent intrasubsegmental tumor recurrence after radiofrequency ablation (RFA) for patients with hepatocellular carcinoma (HCC). Methods We studied 303 consecutive patients with HCC (single nodule and tumor diameter ≤30 mm) who received RFA between January 2005 and April 2015; 268 patients received touch ablation using a monopolar or bipolar RFA device, and 35 received no-touch ablation using a bipolar RFA device. The pretreatment arterial and portal phase dynamic computed tomography or magnetic resonance images were classified into four enhancement patterns. Type 1 and Type 2 are homogeneous enhancement patterns without or with increased arterial blood flow, respectively. Type 3 is a heterogeneous enhancement pattern with a septum-like structure, and Type 4 is an irregularly shaped ring structure enhancement pattern. Results With regard to intrasubsegmental tumor recurrence, among the 268 patients who underwent the touch ablation procedure, tumors recurred in 52 (19.4%) patients, and among the 35 patients who underwent the no-touch ablation procedure, tumors recurred in one (2.9%) patient. Cumulative intrasubsegmental tumor recurrence rates tended to be higher with touch ablation ( P = 0.083). Multivariate Cox proportional hazards analysis revealed that ablation procedure (touch ablation, hazard ratio [HR] 10.32, P = 0.032), type of enhancement pattern (Type 3, HR 3.05, P = 0.006; and Type 4, HR 8.87, P < 0.001) and serum des-γ-carboxyprothrombin level (≥100 AU/L; HR 2.73, P = 0.035) were significant predictors for intrasubsegmental recurrence. Conclusion The no-touch pincer ablation procedure has the potential to prevent intrasubsegmental recurrence after RFA for patients with HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
38. Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease.
- Author
-
Ogata, Fumihiro, Kobayashi, Masahiro, akuta, Norio, Osawa, Mitutaka, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Mariko, Saitoh, Satoshi, Suzuki, Yoshiyuki, Suzuki, Fumitaka, arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu
- Subjects
ANTIVIRAL agents ,DRUG therapy ,CHRONIC diseases ,HEPATITIS C ,HEPATOCELLULAR carcinoma ,LIVER diseases ,MULTIVARIATE analysis ,GENOTYPES - Abstract
Objectives: There is little information on the risk factors for hepatocellular carcinoma (HCC) and outcome of treatment with an all-oral combination of direct-acting antiviral regimens following eradication of hepatitis C virus (HCV) RNA. Methods: The study subjects were 1,170 patients with HCV genotype 1-related chronic liver disease treated with either NS5A inhibitor plus NS3/4A protease inhibitor (n = 707), NS5A inhibitor plus NS5B polymerase inhibitor (n = 345), or NS5A inhibitor, NS3/4A protease inhibitor plus ritonavir (n = 118), for 12-24 weeks. All patients were free of HCC before and during therapy. Results: In this retrospective study, 22 patients developed HCC during the follow-up (time from the end of antiviral therapy until the last visit: 1.3 years). At 1 and 2 years after completion of the treatment, the cumulative HCC rates for the whole group were 1.8 and 2.3%, respectively, and 1.4 and 1.8%, respectively, for 1,065 patients who showed sustained virological response (SVR). The risk factors for HCC identified by multivariate analysis were hypoalbuminemia, thrombocytopenia, a high α-fetoprotein level, and non-SVR for all patients, and hypoalbuminemia and a high α-fetoprotein level for patients with SVR. Conclusion: Eradication of HCV RNA by direct-acting antiviral regimens might reduce the risk of HCC. Albumin and α-fetoprotein levels are significant risk factors for HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
39. Beneficial effect of arterial embolization with warmed miriplatin for multiple hepatocellular carcinoma.
- Author
-
Ikeda, Kenji, Kawamura, Yusuke, Kobayashi, Masahiro, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Akuta, Norio, Saitoh, Satoshi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, and Kumada, Hiromitsu
- Subjects
LIVER cancer ,RESPONSE rates ,CHEMOEMBOLIZATION ,SPONTANEOUS cancer regression - Abstract
Aim The effect of transcatheter arterial chemoembolization (TACE) is not necessarily sufficient in patients with multiple hepatocellular carcinoma (HCC). We evaluated the antitumor activity and adverse events of TACE using warmed miriplatin suspension for multiple HCC. Methods Seventy patients with multiple HCC received TACE using warmed miriplatin/lipiodol suspension, including patients who were TACE-naïve (group A, n = 5), those undergoing initial TACE after radical therapies (group B, n = 31), and those with a history of repeated TACE (group C, n = 34). Median tumor size was 19.5 mm and a median of four nodules. Results Complete necrosis (TE 4) and partial necrosis (TE 3) of 50% or more were attained in 24 and 19 patients at 3 months after TACE, respectively. Response rates (TE 4 + TE 3) were 60.0% in group A, 83.9% in group B, and 41.2% in group C ( P = 0.038). Survival rates of all patients after TACE were 82.6% after 1 year, 65.6% after 2 years, and 47.7% after 3 years. Three-year survival rates of patients in groups A, B, and C were 53.3%, 78.8%, and 29.7%, respectively ( P = 0.0029). Conclusion Transcatheter arterial chemoembolization using warmed miriplatin induced high response rate in multiple HCC, and the rate was significantly high in those patients with recurrent multiple HCCs after curative therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
40. Usefulness and limitations of balloon-occluded transcatheter arterial chemoembolization using miriplatin for patients with four or fewer hepatocellular carcinoma nodules.
- Author
-
Kawamura, Yusuke, Ikeda, Kenji, Fujiyama, Shunichiro, Hosaka, Tetsuya, Kobayashi, Masahiro, Saitoh, Satoshi, Sezaki, Hitomi, Akuta, Norio, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, and Kumada, Hiromitsu
- Subjects
LIVER cancer ,ORGANOPLATINUM compounds ,MEDICAL balloons ,CHEMOEMBOLIZATION ,TREATMENT effectiveness ,THERAPEUTICS - Abstract
Aim The aim of this study is to clarify the usefulness and limitations of balloon-occluded transcatheter arterial chemoembolization (B-TACE) using miriplatin for patients with four or fewer hepatocellular carcinoma (HCC) nodules. Methods We studied 47 nodules in 30 consecutive patients who received miriplatin by B-TACE to treat HCC with four or fewer nodules per patient. The treatment effect was evaluated using the Response Evaluation Criteria in Cancer of the Liver. Results Nodules were divided according to the presence or absence of portal vein visualization during B-TACE. In the presence group, dynamic computed tomography at 3 months post-therapy showed Response Evaluation Criteria in Cancer of the Liver treatment effect (TE) 4 in 88% (14/16), TE3 in 0% (0/16), TE2 in 0% (0/16), TE1 in 12% (2/16), and objective response in 88% of nodules. In the absence group, the results were TE4 in 35% (11/31), TE3 in 13% (4/31), TE2 in 26% (8/31), TE1 in 26% (8/31), and objective response decreased to 48% of nodules. In addition to typical hypervascular nodules, we treated three nodules with irregular ring enhancement that predicted poorly differentiated HCC and four nodules that included a hypoenhancement area that predicted well to moderately differentiated HCC. All irregular ring enhancement nodules achieved TE4. Other nodules that were predicted to be well to moderately differentiated HCC did not have portal vein visualization during B-TACE and could not achieve TE4. Conclusion Balloon-occluded transcatheter arterial chemoembolization is a useful technique for treatment of classical hypervascular HCC, and portal vein visualization during the B-TACE procedure may provide more favorable local control. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
41. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.
- Author
-
Kobayashi, Masahiro, Suzuki, Fumitaka, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Hosaka, Tetsuya, Akuta, Norio, Suzuki, Yoshiyuki, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu
- Abstract
The aim of this study was to assess the rate of development of hepatocellular carcinoma (HCC) in patients who achieved sustained virologic response (SVR) by direct antiviral agents (DAA). We retrospectively evaluated patients who achieved SVR by oral DAA interferon-free regimens (n = 77) (daclatasvir/asunaprevir [n = 67], ombitasvir/paritaprevir/ritonavir [n = 9], and telaprevir [n = 1]) and by pegylated-interferon plus ribavirin (Peg-IFN/RBV, n = 528). In all patients, the background was chronic hepatitis or cirrhosis caused by HCV genotype 1b. During a median follow-up period of 4.0 years, two (2.6%) of DAA-treated patients developed HCC. The 3- and 5-year cumulative HCC development rates were 1.30% and 3.03%, respectively, in the DAA group, and 1.02% and 2.19 % in the Peg-IFN/RBV group ( P not significant). In patients with Fib-4 score of >3.25, the 3-year HCC development rates were 4.35% and 3.95%, whereas those of the 5 year were 9.66% and 8.37%, in the DAA and Peg-IFN/RBV group, respectively. In patients with Fib-4 score of ≤3.25, none of the DAA group developed HCC, whereas 0.48% at 3-year and 1.05% at 5-year of patients of the Peg-IFN/RBV group did. Propensity score analysis using the inverse probability of treatment weights (IPTW) also showed no significant difference in HCC development rate between the two groups. Serum AFP gradually and similarly decreased after initiation of antiviral therapy in both groups. Our data indicate that the HCC risk rate after SVR is similar regardless of whether the latter was achieved by DAA or IFN-based regimens. J. Med. Virol. 89:476-483, 2017. © 2016 Wiley Periodicals, Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
42. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
- Author
-
akuta, Norio, Kobayashi, Masahiro, Suzuki, Fumitaka, Sezaki, Hitomi, Fujiyama, Shunichiro, Kawamura, Yusuke, Hosaka, Tetsuya, Kobayashi, Mariko, Saitoh, Satoshi, Suzuki, Yoshiyuki, arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu
- Subjects
THERAPEUTIC use of interferons ,ANTIVIRAL agents ,HEPATOCELLULAR carcinoma ,BIOMARKERS ,HEPATITIS C ,LIVER diseases ,MULTIVARIATE analysis ,RNA ,FIBROSIS ,BODY mass index ,TREATMENT effectiveness ,RETROSPECTIVE studies ,GENOTYPES ,DIAGNOSIS - Abstract
Background and Aims: Predictive factors for hepatocarcinogenesis following eradication of hepatitis C virus (HCV) RNA by antiviral therapy with direct-acting antivirals are unknown. Especially the impact of treatment with or without interferon on hepatocarcinogenesis is not clear. Methods: A total of 958 patients with HCV genotype 1-related chronic liver disease and a sustained virological response defined as negative HCV RNA 24 weeks after cessation of antiviral therapy with direct-acting antivirals (triple therapy of NS3/4A protease inhibitor/peginterferon/ribavirin or all-oral combination therapy with NS3/4A protease inhibitor plus NS5A inhibitor) were included in a retrospective study. None of the patients had hepatocellular carcinoma before and during antiviral therapy. Results: In all, 14 patients developed hepatocellular carcinoma during follow-up, and the development rate per 1,000 person-years was 7.35. The cumulative hepatocarcinogenesis rates were 4.2 and 4.2% at the end of 5 and 7 years, respectively. Multivariate analysis identified fibrosis 4 (FIB4) index (= 2.7) and body mass index (= 23.0) as determinants of hepatocarcinogenesis, but they did not identify the treatment regimen. In patients with a FIB4 index = 2.7, the hepatocarcinogenesis rates with the interferon regimen were not different from those for the regimen without interferon, regardless of gender. Conclusion: Liver fibrosis and body mass index, but not treatment regimen, are important predictors of hepatocarcinogenesis following eradication of HCV RNA by direct-acting antivirals. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
43. Three-Dimensional Imaging Using Contrast-Enhanced and Three-Dimensional Ultrasound Techniques in the Ablative Zone Treated with a Multipolar Radiofrequency Ablation System for Hepatocellular Carcinoma.
- Author
-
Tanaka, Takashi, Ikeda, Kenji, Sorin, Yushi, Fukushima, Taito, Kawamura, Yusuke, Kobayashi, Masahiro, and Kumada, Hiromitsu
- Subjects
CATHETER ablation ,HEPATOCELLULAR carcinoma ,THREE-dimensional imaging ,DATA analysis software ,DESCRIPTIVE statistics - Abstract
Objectives: The aim of this study was to generate three-dimensional (3D) images of the ablative zone in patients with hepatocellular carcinoma (HCC) treated with multipolar radiofrequency ablation (RFA) using contrast-enhanced ultrasound (CEUS) and 3DUS and to investigate the shape of the ablative zone among several patterns after insertion of two or three electrodes. Methods: This study included 16 patients and 20 HCCs treated with a multipolar RFA system. All patients underwent CEUS within 14 days after multipolar RFA therapy. The 3D scanning functionality of the LOGIQ E9 US imaging system (GE Healthcare, Milwaukee, Wis., USA), which acquires volume data using a manually controlled sweep on perfusion defects of CEUS, was used in this study to acquire CEUS/3DUS data. The ablative-area shapes resulting from three insertion patterns were investigated, using two electrodes (T20-T20 and T30-T30) or three electrodes (T30-T30-T30). Results: The resulting shapes using two electrodes were globule-like (T20-T20) or elliptical (T30-T30). The shape using three electrodes (T30-T30-T30) was almost ellipse- like but slightly irregular. Conclusions: Generating 3D images using CEUS/3DUS techniques is simple and useful for evaluating the shape of the ablative area, and these images provide informational or educational tools for patients and medical staff associated with multipolar RFA procedures. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
44. Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma.
- Author
-
Kunimoto, Hideo, Ikeda, Kenji, Sorin, Yushi, Fujiyama, Shunichiro, Kawamura, Yusuke, Kobayashi, Masahiro, Sezaki, Hitomi, Hosaka, Tetsuya, Akuta, Norio, Saitoh, Satoshi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, and Kumada, Hiromitsu
- Subjects
HEPATITIS C ,HEPATOCELLULAR carcinoma ,STATISTICAL sampling ,SURVIVAL ,DISEASE relapse ,VIRAL load ,RETROSPECTIVE studies ,THERAPEUTICS - Abstract
Background and Aims: A sustained virological response (SVR) decreases the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C. We investigated the longterm outcomes of patients who developed HCC after achieving SVR with interferon therapy. Patients: Of 75 patients who developed HCC after SVR, 40 patients underwent radical therapies (SVR group). From 436 patients undergoing surgical resection for hepatitis C virus-positive HCC, 80 patients were randomly chosen as a control cohort, after adjusting for age, gender, and extent of hepatic fibrosis (non- SVR group). Patients were observed for a median of 5.08 years. Results: HCC recurrence was found in 16 SVR patients and in 66 non-SVR patients. The respective HCC recurrence rates of SVR and non-SVR patients were 23 and 56% at 3 years, 42 and 77% at 5 years, and 53 and 90% at 10 years (p = 0.001). The respective overall survival rates in the SVR and non-SVR groups were 93 and 68% at 5 years, 88 and 34% at 10 years, and 53 and 21% at 15 years (p = 0.001). Conclusion: Although SVR patients had a significantly lower HCC recurrence rate than the non-SVR patients, the cumulative recurrence rate of SVR patients increased to 86% at 15 years. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
45. Randomized Controlled Trial Comparing the Efficacy of Impedance Control and Temperature Control of Radiofrequency Interstitial Thermal Ablation for Treating Small Hepatocellular Carcinoma.
- Author
-
Fukushima, Taito, Ikeda, Kenji, Kawamura, Yusuke, Sorin, Yushi, Hosaka, Tetsuya, Kobayashi, Masahiro, Saitoh, Satoshi, Sezaki, Hitomi, Akuta, Norio, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, and Kumada, Hiromitsu
- Subjects
HEPATOCELLULAR carcinoma ,ACADEMIC medical centers ,CATHETER ablation ,TEMPERATURE ,RANDOMIZED controlled trials ,DESCRIPTIVE statistics ,MANN Whitney U Test ,THERAPEUTICS - Abstract
Objectives: A randomized controlled trial was conducted to evaluate the efficacy of impedance control of a radiofrequency interstitial thermal ablation system (RITA) used to treat hepatocellular carcinoma (HCC). Methods: Fifteen patients with hypervascular HCCs <20 mm in diameter were randomly treated with radiofrequency ablation (RFA) using conventional temperature control (group A) or impedance control methods (group B). RITA needle electrodes were used in all cases. We compared ablation time, extent of lesion ablation, and energy use between the two groups. Results: The median long and short diameters of the axial cross sections of radiofrequency-induced necrotic areas visualized by CT were 32 mm (range, 26-36) and 25 mm (20-31) in group A and 32 mm (28-40) and 31 mm (24-37) in group B, respectively. The short diameter of group B patients was significantly greater than that of group A patients (p = 0.029). The median ablation time was 18.8 min in group A and 13.4 min in group B, thus significantly shorter in group B (p = 0.001). The energy requirement did not differ significantly between the groups. Conclusions: Impedance control of the RITA system resulted in an increased size of the ablation zone and a decreased ablation time. © 2015 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
46. Potential of a no-touch pincer ablation procedure for small hepatocellular carcinoma that uses a multipolar radiofrequency ablation system: An experimental animal study.
- Author
-
Kawamura, Yusuke, Ikeda, Kenji, Fukushima, Taito, Hara, Tasuku, Hosaka, Tetsuya, Kobayashi, Masahiro, Saitoh, Satoshi, Sezaki, Hitomi, Akuta, Norio, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, and Kumada, Hiromitsu
- Subjects
LIVER cancer ,ABLATION techniques ,CATHETER ablation ,LABORATORY swine ,CARBONIZATION ,MEDICAL statistics - Abstract
Aim Treatment of hepatocellular carcinoma located on the liver surface is frequently difficult because direct puncture of the tumor must be avoided during needle insertion. The aim of this study was to investigate the utility of a no-touch pincer ablation procedure that uses a multipolar radiofrequency ablation ( RFA) system for a tumor located on the liver surface. Methods The experimental animals were three pigs, and RFA was performed with two internally cooled bipolar electrodes. Three ablative procedures were compared: linear insertion at regular 13-mm intervals (pattern 1; virtual target tumor size, <10 mm); fan-shape insertion, maximum interval 20 mm (pattern 2; virtual target tumor size, <15 mm); and 25 mm (pattern 3; virtual target tumor size, <20 mm). All electrodes were inserted at a 30-mm depth. For patterns 1 and 2, ablation was performed on three other parts of the liver, and for pattern 3, ablation was performed on two other parts. Results For the median transverse and longitudinal diameter to the shaft, with the pattern 1 procedure, the ablative areas were 32 mm × 30 mm, and with the pattern 2 procedure, the ablative areas were 27 mm × 30 mm with carbonization of the liver surface. In contrast, with the pattern 3 procedure, the ablative areas were 45 mm × 26 mm; however, the ablative margin did not reach the surface, and carbonization was not apparent. Conclusion The no-touch pincer ablation procedure (with an electrode interval of ≤20 mm) may be useful when performed with two internally cooled bipolar electrodes for small nodules that protrude from the liver surface. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
47. Prevention of Disease Progression with Anti-Inflammatory Therapy in Patients with HCV-Related Cirrhosis: A Markov Model.
- Author
-
Ikeda, Kenji, Kawamura, Yusuke, Kobayashi, Masahiro, Fukushima, Taito, Sezaki, Hitomi, Hosaka, Tetsuya, Akuta, Norio, Saitoh, Satoshi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, and Kumada, Hiromitsu
- Subjects
ANTI-inflammatory agents ,HEPATOCELLULAR carcinoma ,THERAPEUTIC use of interferons ,CIRRHOSIS of the liver ,ACADEMIC medical centers ,CHI-squared test ,FISHER exact test ,HEPATITIS C ,LONGITUDINAL method ,U-statistics ,DATA analysis software ,DESCRIPTIVE statistics ,LOG-rank test ,DISEASE complications ,PREVENTION - Abstract
Background: The significance of anti-inflammatory therapy has not been fully evaluated in hepatitis C virus (HCV)-related cirrhosis. Patients and Methods: We analyzed stepwise progression rates from cirrhosis to hepatocellular carcinoma (HCC) and to death using a Markov model in 1,280 patients with HCV-related cirrhosis. During the observation period, 303 patients received interferon and 736 received glycyrrhizin injections as anti-inflammatory therapy. Results: In the entire group, annual progression rates from cirrhosis to HCC and from cirrhosis to death were 6.8 and 1.9%, and the rate from HCC to death was 19.0%. When sustained virological response (SVR) or biochemical response (BR) was attained with interferon, the annual rate to HCC decreased to 2.6%. On the contrary, the progression rates to HCC and to death in the patients without SVR and BR were 7.2 and 2.0%, respectively (p < 0.0001). Continuous interferon administration significantly decreased the carcinogenesis rate to 5.5% (p = 0.0087). In the analysis of the remaining patients with high alanine transaminase of 75 IU/l or more but without interferon response or without interferon administration, glycyrrhizin injection significantly decreased annual non-progression probability (no glycyrrhizin 88.0% vs. glycyrrhizin therapy 92.3%, p = 0.00055). Conclusion: Glycyrrhizin injection therapy is useful in the prevention of disease progression in interferon-resistant or intolerant patients with HCV-related cirrhosis. © 2014 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
48. Clinical significance of hepatectomy for primary biliary cirrhosis patients with hepatocellular carcinoma: Report of a single center case series and review of the published work.
- Author
-
Sasaki, Kazunari, Matsuda, Masamichi, Ohkura, Yu, Kawamura, Yusuke, Inoue, Masafumi, Suzuki, Yoshiyuki, Hashimoto, Masaji, Ikeda, Kenji, Kumada, Hiromitsu, and Watanabe, Goro
- Subjects
HEPATECTOMY ,SURGICAL excision ,STANDARD deviations ,LIVER cancer ,VIRAL hepatitis ,LIVER transplantation - Abstract
Aim Hepatectomy for hepatocellular carcinoma ( HCC) in patients with primary biliary cirrhosis ( PBC) has seldom been reported, and the clinical significance of this procedure remains unclear, although HCC has often been observed in end-stage PBC patients. Methods To understand the characteristics of hepatectomy on HCC in PBC patients, we examined seven cases at our institute, as well as 22 reported hepatectomy cases in the English-language and Japanese published work. Furthermore, to assess the treatment efficacy of hepatectomy for HCC in PBC patients, we compared these patients with viral hepatitis patients who underwent hepatectomies at our institute during the same period. Results In the review of 29 cases, more than 70% of the patients were aged over 65 years, and the mean Mayo risk score was low at 5.17. The resected tumors were mainly solitary (79%), and the median maximum tumor size was 37 mm. Approximately two-thirds of the patients met the Milan criteria. In the comparison between the PBC and viral hepatitis cases, there were no differences in the postoperative prognoses, although the tumor size was greater in the PBC cases. Conclusion Hepatectomy for HCC in selected PBC cases is a feasible and potentially curative treatment option, similar to hepatectomy for HCC in viral hepatitis patients. This procedure is particularly useful for patients with preserved liver function who are not ideal candidates for liver transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
49. Factors associated with early cancer-related death after curative hepatectomy for solitary small hepatocellular carcinoma without macroscopic vascular invasion.
- Author
-
Sasaki, Kazunari, Matsuda, Masamichi, Ohkura, Yu, Kawamura, Yusuke, Inoue, Masafumi, Hashimoto, Masaji, Ikeda, Kenji, Kumada, Hiromitsu, and Watanabe, Goro
- Abstract
Background Unexpected early cancer-related death ( ECRD) within 2 years due to recurrence after curative hepatectomy for solitary small (<5 cm) hepatocellular carcinoma without macroscopic vascular invasion ( SSHCC) is occasionally observed. Method A total of 415 patients were enrolled (19 patients with ECRD and 396 patients with non- ECRD) to elucidate the risk factors of ECRD after curative hepatectomy for SSHCC. They were initially compared by limiting variables to preoperative factors to reveal predictors that could enable the modification of primary treatment. Subsequently, the same analysis was performed with all variables, including perioperative and histological factors. Results In the preoperative factors, tumor size > 3 cm and elevation of tumor marker level were independent predictors of ECRD. In the analysis with all variables, excessive intraoperative blood loss, poor differentiation, and microscopic vascular invasion were predictors of ECRD. In the recurrence patterns, 79% of ECRD presented as advanced (four or more lesions) or extra-hepatic recurrence, whereas these accounted for 18% in the non- ECRD. Conclusion Excessive blood loss during the operation and histopathological findings of microscopic vascular invasion and poor differentiation are predictive factors of cancer-related death within 2 years of a hepatectomy for SSHCC. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
50. Transcriptome Profiling of Archived Sectioned Formalin-Fixed Paraffin-Embedded (AS-FFPE) Tissue for Disease Classification.
- Author
-
Kojima, Kensuke, April, Craig, Canasto-Chibuque, Claudia, Chen, Xintong, Deshmukh, Manjeet, Venkatesh, Anu, Tan, Poh Seng, Kobayashi, Masahiro, Kumada, Hiromitsu, Fan, Jian-Bing, and Hoshida, Yujin
- Subjects
NOSOLOGY ,FORMALDEHYDE ,BIOMARKERS ,LIVER cancer ,GENETIC transcription ,CIRRHOSIS of the liver ,RETROSPECTIVE studies - Abstract
Background: Archived tissues from previously completed prospective trials represent invaluable resource for biomarker development. However, such specimens are often stored as sections on glass slides, in which RNA is severely degraded due to prolonged air exposure. We evaluated whether a proportion of archived sectioned formalin-fixed paraffin-embedded (AS-FFPE) tissues yield transcriptome profiles comparable to freshly cut (FC) FFPE tissues, which can be used for retrospective class prediction analysis. Methods: Genome-wide transcriptome profiles of 6 to 7-year-old AS-FFPE tissue sections (generated from 5 to 16-year-old blocks) of 83 hepatocellular carcinoma (HCC) and 47 liver cirrhosis samples were generated by using whole-genome DASL assay (Illumina) and digital transcript counting (nCounter) assay (NanoString), and gene signature-based prediction of HCC subclasses and prognosis was compared with previously generated FC-FFPE profiles from the same tissue blocks. Results: RNA quality and assay reproducibility of AS-FFPE RNA were comparable to intermediate to poor quality FC-FFPE samples (RNA Integrity Number: up to 2.50, R-square for technical replicates: up to 0.93). Analyzable transcriptome profiles were obtained in 64 (77%) HCC and 36 (77%) cirrhosis samples. Statistically more confident predictions based on random resampling-based method (nearest template prediction) were obtained in 37 (58%) HCC and 13 (36%) cirrhosis samples. Predictions made in FC-FFPE profiles were reproduced in 36 (97%) HCC and 11 (85%) cirrhosis AS-FFPE profiles. nCounter assay was tested in 24 cirrhosis samples, which yielded confident prediction in 15 samples (63%), of which 10 samples (67%) showed concordant predictions with FC-FFPE profiles. Conclusions: AS-FFPE tissues yielded poorer quality RNA and transcriptome profiles compared to FC-FFPE tissues. Statistically more confident class prediction was feasible in 37 of 83 HCC samples and 13 of 47 cirrhosis samples. These results suggest that AS-FFPE tissues can be regarded as a resource for retrospective transcriptome-based class prediction analysis when they are the only available materials. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.